Erratum: Mitotoxicity in distal symmetrical sensory peripheral neuropathies (Nature Reviews Neurology (2014) 10 (326-336) DOI: 10.1038/nrneurol.2014.77);Mitotoxicity in distal symmetrical sensory peripheral neuropathies

Nature Reviews Neurology

Volumn 10, Issue 6, 2014, Pages 326-336

  Bennett, Gary J ^a   Doyle, Timothy ^b   Salvemini, Daniela ^b  

^a MCGILL UNIVERSITY   (Canada)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETA TUBULIN; BORTEZOMIB; DIDANOSINE; EFAVIRENZ; GLUTATHIONE PEROXIDASE; GLYCOPROTEIN GP 120; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEVACECARNINE; MANGANESE SUPEROXIDE DISMUTASE; OLESOXIME; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RILPIVIRINE; STAVUDINE; TAXANE DERIVATIVE; THIOCTIC ACID; TRANSACTIVATOR PROTEIN; VINCA ALKALOID; VINCRISTINE; VPR PROTEIN; ZALCITABINE; ZIDOVUDINE; ACETYLCYSTEINE; ANTIOXIDANT; GLUTATHIONE; N TERT BUTYL ALPHA PHENYLNITRONE; N(G) NITROARGININE METHYL ESTER; PORPHYRIN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SRI 110; SRI 6; SS 31; TEMPOL; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN;

ALLODYNIA; ANTIOXIDANT ACTIVITY; BURNING SENSATION; CANCER CHEMOTHERAPY; CELL ENERGY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISTAL SYMMETRICAL SENSORY PERIPHERAL NEUROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NERVE CELL DEGENERATION; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PINS AND NEEDLES SENSATION; PRIORITY JOURNAL; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSATION; SENSORY NERVE CELL; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; ARTHRALGIA; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSESTHESIA; ENERGY YIELD; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAEPIDERMAL NERVE FIBRE; NERVE FIBER; NERVE STIMULATION; NEUROPATHY; SENSORY NERVE;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; HUMANS; MITOCHONDRIA; NEURALGIA; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84902276450     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.120     Document Type: Erratum

References (93)

1. Quasthoff, S. &Hartung, H. P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 249, 9-17 (2002).
2. Argyriou, A. A., Iconomou, G. &Kalofonos, H. P. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 112, 1593-1599 (2008).
3. Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L. &Feldman, E. L. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 11, 521-534 (2012).
4. Centner, C. M., Bateman, K. J. &Heckmann, J. M. Manifestations of HIV infection in the peripheral nervous system. Lancet Neurol. 12, 295-309 (2013).
5. Lauria, G., Merkies, I. S. &Faber, C. G. Small fibre neuropathy. Curr. Opin. Neurol. 25, 542-549 (2012).
6. Flatters, S. J. &Bennett, G. J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122, 245-257 (2006).
7. Xiao, W. H. &Bennett, G. J. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 153, 704-709 (2012).
8. Zheng, H., Xiao, W. H. &Bennett, G. J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp. Neurol. 232, 154-161 (2011).
9. Zheng, H., Xiao, W. H. &Bennett, G. J. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp. Neurol. 238, 225-234 (2012).
10. Webster, R. G., Brain, K. L., Wilson, R. H., Grem, J. L. &Vincent, A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146, 1027-1039 (2005).
11. Loprinzi, C. L. et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J. 13, 399-403 (2007).
12. Kleggetveit, I. P. et al. High spontaneous activity of C nociceptors in painful polyneuropathy. Pain 153, 2040-2047 (2012).
13. Xiao, W. H. &Bennett, G. J. Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A fiber and C fiber primary afferent neurons and its suppression by acetyl l carnitine. Pain 135, 262-270 (2008).
14. Xiao, W. H. et al. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 199, 461-469 (2011).
15. Erecinska, M. &Silver, I. A. Ions and energy in mammalian brain. Prog. Neurobiol. 43, 37-71 (1994).
16. Xiao, W. H., Zheng, H. &Bennett, G. J. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 203, 194-206 (2012).
17. Han, C. et al. The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2013-306095.
18. Argyriou, A. A. et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer 119, 3570-3577 (2013).
19. Boyette-Davis, J. A. et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J. Pain 12, 1017-1024 (2011).
20. Koskinen, M. J. et al. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Res. 31, 4413-4416 (2011).
21. Loseth, S., Stalberg, E., Jorde, R. &Mellgren, S. I. Early diabetic neuropathy: Thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J. Neurol. 255, 1197-1202 (2008).
22. Sumner, C. J., Sheth, S., Griffin, J. W., Cornblath, D. R. &Polydefkis, M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60, 108-111 (2003).
23. Polydefkis, M. et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 58, 115-119 (2002).
24. Herrmann, D. N., Griffin, J. W., Hauer, P., Cornblath, D. R. &McArthur, J. C. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 53, 1634-1640 (1999).
25. Nebuchennykh, M., Loseth, S., Lindal, S. &Mellgren, S. I. The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy. J. Neurol. 256, 1067-1075 (2009).
26. Bennett, G. J., Liu, G. K., Xiao, W. H., Jin, H. W. &Siau, C. Terminal arbor degeneration-A novel lesion produced by the antineoplastic agent paclitaxel. Eur. J. Neurosci. 33, 1667-1676 (2011).
27. Siau, C., Xiao, W. &Bennett, G. J. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp. Neurol. 201, 507-514 (2006).
28. Jin, H. W., Flatters, S. J., Xiao, W. H., Mulhern, H. L. &Bennett, G. J. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl l carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp. Neurol. 210, 229-237 (2008).
29. Janes, K. et al. Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite- mediated post-translational nitration of mitochondrial superoxide dismutase. Pain 154, 2432-2440 (2013).
30. Barriere, D. A. et al. Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization. Pain 153, 553-561 (2012).
31. Joseph, E. K. &Levine, J. D. Mitochondrial electron transport in models of neuropathic and inflammatory pain. Pain 121, 105-114 (2006).
32. Kokotis, P. et al. Polyneuropathy induced by HIV disease and antiretroviral therapy. Clin. Neurophysiol. 124, 176-182 (2013).
33. Dalakas, M. C., Semino-Mora, C. &Leon-Monzon, M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab. Invest. 81, 1537-1544 (2001).
34. Lehmann, H. C., Chen, W., Borzan, J., Mankowski, J. L. &Höke, A. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann. Neurol. 69, 100-110 (2011).
35. Campenot, R. B. &Eng, H. Protein synthesis in axons and its possible functions. J. Neurocytol. 29, 793-798 (2000).
36. Mocchetti, I., Bachis, A. &Avdoshina, V. Neurotoxicity of human immunodeficiency virus 1: viral proteins and axonal transport. Neurotox. Res. 21, 79-89 (2012).
37. Herzberg, U. &Sagen, J. Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis. J. Neuroimmunol. 116, 29-39 (2001).
38. Wallace, V. C. et al. Characterization of rodent models of HIV-gp120 and anti retroviral associated neuropathic pain. Brain 130, 2688-2702 (2007).
39. Kamerman, P. R. et al. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J. Peripher. Nerv. Syst. 17, 19-31 (2012).
40. Melli, G., Keswani, S. C., Fischer, A., Chen, W. &Hoke, A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 129, 1330-1338 (2006).
41. Norman, J. P. et al. HIV1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS ONE 3, e3731 (2008).
42. Lecoeur, H. et al. HIV 1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase. Cell. Death Dis. 3, e282 (2012).
43. Deniaud, A., Brenner, C. &Kroemer, G. Mitochondrial membrane permeabilization by HIV 1 Vpr. Mitochondrion 4, 223-233 (2004).
44. Huang, C. Y., Chiang, S. F., Lin, T. Y., Chiou, S. H. &Chow, K. C. HIV 1 Vpr triggers mitochondrial destruction by impairing Mfn2-mediated ER mitochondria interaction. PLoS ONE 7, e33657 (2012).
45. Kitayama, H. et al. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J. Virol. 82, 2528-2542 (2008).
46. Leung, G. P. Iatrogenic mitochondriopathies: A recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors. Adv. Exp. Med. Biol. 942, 347-369 (2012).
47. Keswani, S. C., Jack, C., Zhou, C. &Hoke, A. Establishment of a rodent model of HIV-associated sensory neuropathy. J. Neurosci. 26, 10299-10304 (2006).
48. Robinson, B., Li, Z. &Nath, A. Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures. J. Neurovirol. 13, 160-167 (2007).
49. Van Steenwinckel, J. et al. Role of spinal serotonin 5 HT2A receptor in 2',3' dideoxycytidine induced neuropathic pain in the rat and the mouse. Pain 137, 66-80 (2008).
50. Huang, W. et al. A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy. Pain 154, 560-575 (2013).
51. Zhu, Y. et al. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain 130, 2011-2023 (2007).
52. Callaghan, B. C., Hur, J. &Feldman, E. L. Diabetic neuropathy: one disease or two? Curr. Opin. Neurol. 25, 536-541 (2012).
53. Papanas, N., Vinik, A. I. &Ziegler, D. Neuropathy in prediabetes: does the clock start ticking early? Nat. Rev. Endocrinol. 7, 682-690 (2011).
54. Sivitz, W. I. &Yorek, M. A. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid. Redox. Signal. 12, 537-577 (2010).
55. Chowdhury, S. K., Smith, D. R. &Fernyhough, P. The role of aberrant mitochondrial bioenergetics in diabetic neuropathy. Neurobiol. Dis. 51, 56-65 (2013).
56. Tomlinson, D. R. &Gardiner, N. J. Glucose neurotoxicity. Nat. Rev. Neurosci. 9, 36-45 (2008).
57. Hinder, L. M., Vincent, A. M., Burant, C. F., Pennathur, S. &Feldman, E. L. Bioenergetics in diabetic neuropathy: what we need to know. J. Peripher. Nerv. Syst. 17 (Suppl. 2), 10-14 (2012).
58. Zenker, J., Ziegler, D. &Chrast, R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 36, 439-449 (2013).
59. Eberhardt, M. J. et al. Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): A possible mechanism of metabolic neuropathies. J. Biol. Chem. 287, 28291-28306 (2012).
60. Fernyhough, P., Roy Chowdhury, S. K. &Schmidt, R. E. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert Rev. Endocrinol. Metab. 5, 39-49 (2010).
61. Roy Chowdhury, S. K. et al. Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 135, 1751-1766 (2012).
62. Chowdhury, S. K. et al. Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment. Diabetes 59, 1082-1091 (2010).
63. Akude, E. et al. Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats. Diabetes 60, 288-297 (2011).
64. Urban, M. J. et al. Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp. Neurol. 235, 388-396 (2012).
65. Saleh, A. et al. Ciliary neurotrophic factor activates NF κB to enhance mitochondrial bioenergetics and prevent neuropathy in sensory neurons of streptozotocin-induced diabetic rodents. Neuropharmacology 65, 65-73 (2013).
66. Vincent, A. M. et al. Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy. Acta Neuropathol. 120, 477-489 (2010).
67. Obrosova, I. G. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6, 638-647 (2009).
68. Golbidi, S., Badran, M. &Laher, I. Diabetes and alpha lipoic acid. Front. Pharmacol. 2, 69 (2011).
69. Stevens, M. J., Obrosova, I., Cao, X., Van Huysen, C. &Greene, D. A. Effects of dl α lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49, 1006-1015 (2000).
70. Melli, G. et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp. Neurol. 214, 276-284 (2008).
71. Boulton, A. J., Kempler, P., Ametov, A. &Ziegler, D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab. Res. Rev. 29, 327-333 (2013).
72. Trevisan, G. et al. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res. 73, 3120-3131 (2013).
73. Gedlicka, C., Scheithauer, W., Schull, B. &Kornek, G. V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J. Clin. Oncol. 20, 3359-3361 (2002).
74. Chiechio, S., Copani, A., Nicoletti, F. &Gereau, R. W. 4th. l acetylcarnitine: A proposed therapeutic agent for painful peripheral neuropathies. Curr. Neuropharmacol. 4, 233-237 (2006).
75. Sima, A. A., Calvani, M., Mehra, M., Amato, A. &Acetyl-l-Carnitine Study Group. Acetyl l carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care 28, 89-94 (2005).
76. Youle, M., Osio, M. &ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV 1 infection. HIV Med. 8, 241-250 (2007).
77. Bianchi, G. et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl l carnitine. Eur. J. Cancer 41, 1746-1750 (2005).
78. Hershman, D. L. et al. Randomized double-blind placebo-controlled trial of acetyl l carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J. Clin. Oncol. 31, 2627-2633 (2013).
79. Xiao, W. H., Zheng, F. Y., Bennett, G. J., Bordet, T. &Pruss, R. M. Olesoxime (cholest 4 en 3 one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain 147, 202-209 (2009).
80. Cassina, A. &Radi, R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch. Biochem. Biophys. 328, 309-316 (1996).
81. Radi, R., Cassina, A., Hodara, R., Quijano, C. &Castro, L. Peroxynitrite reactions and formation in mitochondria. Free Radic. Biol. Med. 33, 1451-1464 (2002).
82. Drose, S. &Brandt, U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 748, 145-169 (2012).
83. Fidanboylu, M., Griffiths, L. A. &Flatters, S. J. Global inhibition of reactive oxygen species (ROS) inhibits paclitaxel-induced painful peripheral neuropathy. PLoS ONE 6, e25212 (2011).
84. Toyama, S. et al. Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies. Anesthesiology 120, 459-473 (2014).
85. Kamboj, S. S., Vasishta, R. K. &Sandhir, R. N acetylcysteine inhibits hyperglycemia-induced oxidative stress and apoptosis markers in diabetic neuropathy. J. Neurochem. 112, 77-91 (2010).
86. Lin, P. C. et al. N acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support. Care Cancer 14, 484-487 (2006).
87. Cascinu, S. et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 20, 3478-3483 (2002).
88. Doyle, T. et al. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J. Neurosci. 32, 6149-6160 (2012).
89. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A. &Freeman, B. A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl Acad. Sci. USA 87, 1620-1624 (1990).
90. Payne, J. E. et al. Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4 ((2 cyclobutyl 1H-imidazo[4,5 b]pyrazin 1 yl)methyl) 7, 8 difluoroquinolin 2(1H)-one (KD7332) Part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models. J. Med. Chem. 53, 7739-7755 (2010).
91. Latremoliere, A. &Woolf, C. J. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J. Pain 10, 895-926 (2009).
92. Rausaria, S. et al. Retooling manganese(III) porphyrin-based peroxynitrite decomposition catalysts for selectivity and oral activity: A potential new strategy for treating chronic pain. J. Med. Chem. 54, 8658-8669 (2011).
93. Rausaria, S. et al. Manganese(III) complexes of bis(hydroxyphenyl) dipyrromethenes are potent orally active peroxynitrite scavengers. J. Am. Chem. Soc. 133, 4200-4203 (2011).